Rhumbline Advisers Day One Biopharmaceuticals, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DAWN
# of Institutions
167Shares Held
72.1MCall Options Held
163KPut Options Held
183K-
Ra Capital Management, L.P. Boston, MA7.87MShares$121 Million1.63% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$99.2 Million11.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$71.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$70 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.78MShares$58.4 Million0.02% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.13B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...